Tunlametinib
- Generic Name
- Tunlametinib
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
适用含抗PD-1/PD-L1治疗失败的NRAS突变的晚期黑色素瘤、结直肠癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
China's National Reimbursement Drug List (NRDL) outlook for 2024
The National Reimbursement Drug List (NRDL) faces budget pressure and competition, with 445 drugs passing formal review in 2024. Oncology, immunology, neurology, and rare diseases see strategic positioning and comparator choices as key. Contract renewals and re-negotiations are under pressure, emphasizing clear messaging and data preparation for NRDL success.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath